Michaela Liedtke

机构：Palo Alto University, Cancer Institute (WIA), Stanford Health Care, Stanford Blood Center, Stanford Medicine, Stanford Cancer Institute, Stanford University · ORCID：0000-0001-8945-5850

发表论文 326 篇 · 总被引 14399 次 · h-index 57

代表论文

• NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025 (2025 · Journal of the National Comprehensive Cancer Network · 被引 44)
• Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology (2026 · Journal of the National Comprehensive Cancer Network · 被引 13)
• Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results. (2025 · Journal of Clinical Oncology · 被引 9)
• Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM) (2025 · Blood · 被引 4)
• Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial (2025 · Blood · 被引 2)
• Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma (2025 · eJHaem · 被引 2)